KAPA: kairospharma.com Company Value to Net Income

Kairos Pharma - graphic logo of issuer KAPA

The development of targeted oncology treatments involves a fierce battle for FDA certification and pressure from pharmaceutical behemoths. High R&D costs and patent protection create significant barriers to entry for new players in the sector. This price action on GURU.Markets shows a PE ratio of -0.30, confirming the status of Kairos Pharma Ltd (KAPA) as an authoritative innovator in the eyes of the medical community.

Price to Earnings Ratio: Kairos Pharma Inc (KAPA) for 09/17/2024 - 11/16/2026

Comprehensive metric breakdowns and analytics for Kairos Pharma Limited (KAPA)

- share price and expert price forecast:
Comprehensive company analysis:KAPA, Kairos Pharma
Flagship merchandise of Kairos Pharma

When assessing the scale of oncology drug development at Kairos Pharma Ltd (KAPA), investors analyze the company's historical P/E ratio to evaluate the relationship between the asset's market value and its net income to determine the investment payback period. A decline in this metric amid clinical successes in treating resistant tumors may signal that the securities are undervalued, although a critical minimum indicates a risk of business insolvency.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ARTV: P/E Multiple|ANL: Market Price to Net Income Ratio|Price to Earnings Ratio VERU|TPST: Company Value to Net Income|Price to Earnings Ratio xiliotx.com (XLO)|Renovaro - Price to Earnings Multiple|Price to Earnings Ratio Mural Oncology MURA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV